A recent study constructed a prognostic model for patients who underwent regorafenib and identified that low carcinoembryonic antigen (CEA), slow rate of tumor progression, and fewer organ metastatic sites were highly correlated with good overall survival [16]. Here, CEACAM5 is linked to neoplasm.